Global Genetic Vaccine Market Size By Type (Recombinant Protein Vaccine, Gene-Based Vaccine), By Application (Human, Animal), By Region, And Segment Forecasts, 2023 to 2032

The Global Genetic Vaccine Market was valued at USD 14.2 billion in 2023 and is projected to reach USD 42.7 billion by 2031, expanding at a CAGR of 14.8% during the forecast period. The increasing prevalence of infectious diseases, rising investments in biotechnology research, and the successful development and deployment of mRNA vaccines during the COVID-19 pandemic have significantly accelerated the adoption of genetic vaccines. These vaccines, which include DNA and RNA-based platforms, offer rapid development timelines, scalable manufacturing, and high efficacy, making them a transformative solution in both preventive and therapeutic immunization.

Drivers

1. Rapid Technological Advancements in Vaccine Platforms

The surge in R&D activities and advancements in mRNA and DNA vaccine technologies are pivotal to the market's growth. These platforms offer adaptability to target various diseases, including emerging viral threats and chronic illnesses.

2. Strong Government and Private Sector Investments

Substantial funding from government health agencies and private biotech firms is supporting clinical trials, regulatory approvals, and global distribution networks, further propelling the market.

3. Rising Demand for Personalized Medicine

Genetic vaccines align with the growing trend toward precision medicine, enabling the design of vaccines tailored to individual genetic profiles or specific populations.

Restraints

1. Regulatory and Ethical Challenges

The approval process for genetic vaccines is rigorous, involving complex regulatory scrutiny to ensure long-term safety and efficacy. Ethical concerns also arise, especially in human genetic modification.

2. High Production and Cold Chain Requirements

Some genetic vaccines, particularly mRNA-based types, require ultra-cold storage and specialized logistics, which can hinder their deployment in low-resource settings.

Opportunity

1. Expansion into Oncology and Autoimmune Disorders

Beyond infectious diseases, genetic vaccines hold immense potential in treating cancers and autoimmune disorders through therapeutic vaccination strategies.

2. Development of Universal Vaccines

Ongoing efforts to create broad-spectrum or universal vaccines against influenza, HIV, and coronaviruses present lucrative opportunities for market players.

3. Market Penetration in Developing Economies

Emerging markets in Asia-Pacific, Latin America, and Africa present untapped potential due to rising healthcare investments and improving vaccine distribution infrastructure.

Market by System Type Insights

Based on system type, the mRNA Vaccine segment accounted for the largest market share in 2023, driven by the success of COVID-19 vaccines like Pfizer-BioNTech and Moderna. The DNA Vaccine segment is also gaining traction, particularly in veterinary applications and as candidates progress through clinical trials for human use. As production technologies improve, DNA vaccines are expected to witness accelerated growth.

Market by End-use Insights

The Human Healthcare segment dominated the market in 2023, accounting for over 80% of total revenue, largely due to pandemic preparedness initiatives and immunization programs. The Veterinary Healthcare segment also presents strong growth potential, especially with genetic vaccines being used for livestock and companion animals to combat zoonotic and economically impactful diseases.

Market by Regional Insights

North America led the global genetic vaccine market in 2023, supported by high healthcare spending, advanced biotechnology infrastructure, and favorable regulatory pathways. Asia-Pacific is expected to record the highest CAGR during the forecast period, driven by rising investments in biotech, expanding healthcare access, and government-backed immunization efforts in countries such as China and India.

Competitive Scenario

Key players in the Global Genetic Vaccine Market include:

Moderna, Inc.

Pfizer Inc.

BioNTech SE

CureVac N.V.

Inovio Pharmaceuticals

Gennova Biopharmaceuticals

Sanofi S.A.

GlaxoSmithKline plc

Zydus Lifesciences

GeneOne Life Science

These companies are focusing on expanding their mRNA and DNA vaccine portfolios, entering strategic collaborations, and enhancing global production capacities. For instance:

In 2024, Moderna launched its RSV genetic vaccine in multiple markets following positive Phase III results.

In 2023, Gennova Biopharmaceuticals received approval in India for its indigenous mRNA vaccine targeting COVID-19 variants.

In 2025, Pfizer and BioNTech announced clinical trials for a combined mRNA-based flu and COVID-19 vaccine booster.

Scope of Work – Global Genetic Vaccine Market

Key Market Developments

2023: Pfizer and BioNTech expanded their mRNA vaccine production facility in Germany to support new pipeline developments.

2024: CureVac and GSK advanced their collaboration with the launch of an mRNA-based rabies vaccine.

2025: Inovio began Phase III trials for its DNA vaccine candidate targeting HPV-related cancers.

FAQs

What is the current market size of the Global Genetic Vaccine Market?

The Global Genetic Vaccine Market was valued at USD 14.2 billion in 2023.

What is the major growth driver of the Global Genetic Vaccine Market?

Technological advancements in mRNA and DNA vaccine platforms and strong government and private funding.

Which is the largest region during the forecast period in the Global Genetic Vaccine Market?

North America held the largest market share in 2023, while Asia-Pacific is projected to grow fastest.

Which segment accounted for the largest market share in Global Genetic Vaccine Market?

The mRNA Vaccine segment led the market in 2023.

Who are the key market players in the Global Genetic Vaccine Market?

Key players include Moderna, Pfizer, BioNTech, CureVac, Inovio, and Gennova Biopharmaceuticals.